Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT04848272
PHASE1
Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury
Sponsor: St Vincent's Institute of Medical Research
View on ClinicalTrials.gov
Summary
Phase 1 study investigating safety of lanadelumab administration to patients with lung injury
Key Details
Gender
All
Age Range
18 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
48
Start Date
2021-08-09
Completion Date
2024-12
Last Updated
2024-04-17
Healthy Volunteers
No
Conditions
Interventions
DRUG
Lanadelumab
Monoclonal antibody that targets active plasma kallikrein
OTHER
Saline control
Saline control
Locations (1)
St Vincent's Hospital Melbourne
Melbourne, Victoria, Australia